Literature DB >> 26646310

[Determination of prognosis using gene expression analyses: Consequences for the indication for radiotherapy?].

René Baumann1, David Krug2.   

Abstract

Mesh：

Substances：

Year:  2016        PMID： 26646310     DOI： 10.1007/s00066-015-0931-2

Source DB:  PubMed          Journal:  Strahlenther Onkol        ISSN： 0179-7158            Impact factor:   3.621


× No keyword cloud information.
  8 in total

1.  Relationship between the prognostic and predictive value of the intrinsic subtypes and a validated gene profile predictive of loco-regional control and benefit from post-mastectomy radiotherapy in patients with high-risk breast cancer.

Authors:  Trine Tramm; Marianne Kyndi; Simen Myhre; Silje Nord; Jan Alsner; Flemming Brandt Sørensen; Therese Sørlie; Jens Overgaard
Journal:  Acta Oncol       Date:  2014-06-24       Impact factor: 4.089

2.  A new molecular predictor of distant recurrence in ER-positive, HER2-negative breast cancer adds independent information to conventional clinical risk factors.

Authors:  Martin Filipits; Margaretha Rudas; Raimund Jakesz; Peter Dubsky; Florian Fitzal; Christian F Singer; Otto Dietze; Richard Greil; Andrea Jelen; Paul Sevelda; Christa Freibauer; Volkmar Müller; Fritz Jänicke; Marcus Schmidt; Heinz Kölbl; Achim Rody; Manfred Kaufmann; Werner Schroth; Hiltrud Brauch; Matthias Schwab; Peter Fritz; Karsten E Weber; Inke S Feder; Guido Hennig; Ralf Kronenwett; Mathias Gehrmann; Michael Gnant
Journal:  Clin Cancer Res       Date:  2011-08-01       Impact factor: 12.531

3.  Identification of a Low-Risk Luminal A Breast Cancer Cohort That May Not Benefit From Breast Radiotherapy.

Authors:  Fei-Fei Liu; Wei Shi; Susan J Done; Naomi Miller; Melania Pintilie; David Voduc; Torsten O Nielsen; Sharon Nofech-Mozes; Martin C Chang; Timothy J Whelan; Lorna M Weir; Ivo A Olivotto; David R McCready; Anthony W Fyles
Journal:  J Clin Oncol       Date:  2015-05-11       Impact factor: 44.544

4.  Molecular portraits of human breast tumours.

Authors:  C M Perou; T Sørlie; M B Eisen; M van de Rijn; S S Jeffrey; C A Rees; J R Pollack; D T Ross; H Johnsen; L A Akslen; O Fluge; A Pergamenschikov; C Williams; S X Zhu; P E Lønning; A L Børresen-Dale; P O Brown; D Botstein
Journal:  Nature       Date:  2000-08-17       Impact factor: 49.962

5.  Association between the 21-gene recurrence score assay and risk of locoregional recurrence in node-negative, estrogen receptor-positive breast cancer: results from NSABP B-14 and NSABP B-20.

Authors:  Eleftherios P Mamounas; Gong Tang; Bernard Fisher; Soonmyung Paik; Steven Shak; Joseph P Costantino; Drew Watson; Charles E Geyer; D Lawrence Wickerham; Norman Wolmark
Journal:  J Clin Oncol       Date:  2010-01-11       Impact factor: 44.544

6.  The genomic expression test EndoPredict is a prognostic tool for identifying risk of local recurrence in postmenopausal endocrine receptor-positive, her2neu-negative breast cancer patients randomised within the prospective ABCSG 8 trial.

Authors:  F Fitzal; M Filipits; M Rudas; R Greil; O Dietze; H Samonigg; S Lax; W Herz; P Dubsky; R Bartsch; R Kronenwett; M Gnant
Journal:  Br J Cancer       Date:  2015-03-24       Impact factor: 7.640

7.  The EndoPredict score provides prognostic information on late distant metastases in ER+/HER2- breast cancer patients.

Authors:  P Dubsky; J C Brase; R Jakesz; M Rudas; C F Singer; R Greil; O Dietze; I Luisser; E Klug; R Sedivy; M Bachner; D Mayr; M Schmidt; M C Gehrmann; C Petry; K E Weber; K Fisch; R Kronenwett; M Gnant; M Filipits
Journal:  Br J Cancer       Date:  2013-10-24       Impact factor: 7.640

8.  EndoPredict improves the prognostic classification derived from common clinical guidelines in ER-positive, HER2-negative early breast cancer.

Authors:  P Dubsky; M Filipits; R Jakesz; M Rudas; C F Singer; R Greil; O Dietze; I Luisser; E Klug; R Sedivy; M Bachner; D Mayr; M Schmidt; M C Gehrmann; C Petry; K E Weber; R Kronenwett; J C Brase; M Gnant
Journal:  Ann Oncol       Date:  2012-10-03       Impact factor: 32.976
  8 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.